Rosetta Genomics (ROSG) Names New Chief Commercial Officer

October 20, 2016 8:53 AM EDT
Get Alerts ROSG Hot Sheet
Trade ROSG Now!
Join SI Premium – FREE

Get the Pulse of the Market with StreetInsider.com's Pulse Picks. Get your Free Trial here.

Rosetta Genomics Ltd. (Nasdaq: ROSG) announces the appointment of Mark R. Willig as Chief Commercial Officer. In this newly created position, Mr. Willig will be responsible for sales, marketing and market access for Rosetta Genomics’ entire portfolio of high-value diagnostic assays. He will report to Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

Throughout his career Mr. Willig has developed and executed global commercial and business strategies for companies ranging from leading start-ups to Fortune 500 molecular diagnostic companies. Most recently he served as Senior Vice President of Sales for CardioDx, Inc., a pioneer in genomic diagnostics, where he grew revenue by more than 500% while increasing testing volume from 21,000 tests to 150,000 tests annually. Previous to that, he was Executive Vice President of Global Sales for Agendia, BV, a leading molecular diagnostic company that develops and markets genomic assays for early stage cancer patients. At Agendia he was responsible for the launch of their diagnostic product portfolio, which under his leadership increased revenue 140% to an annual run rate of $30 million. At both of these organizations Mr. Willig was responsible for securing positive medical policy and contracting with the first commercial payers.

Previously, Mr. Willig was Vice President of Global Sales at Thermo Fisher Scientific, where he had global responsibility for a $280 million dollar business unit. Mr. Willig was also the Chief Executive Officer at PrognostiX, a Cleveland Clinic spin-off diagnostic company. He also held several key commercial roles at Abbott Laboratories Diagnostics Division and was the first commercial leader at Myriad Genetics, where he launched the first genetic test for hereditary breast and ovarian cancer, which resulted in a 200% CAGR over five years.

“We are delighted to have Mark join our team at this pivotal juncture in the commercialization of our unique and evolving product portfolio. His proven ability to build sales platforms and drive growth for molecular diagnostic products will further enhance the commercial and clinical adoption of our first-of-its-kind microRNA classifier for indeterminate thyroid nodules as well as our urologic oncology and solid tumor offerings,” noted Mr. Berlin.

“With approximately $1.5 million in gross billings for RosettaGX Reveal™ since commercial launch in early 2016 and with strong monthly volume growth, we are well positioned to build on this momentum and increase our market share in the $350 million U.S. market for molecular classifiers for indeterminate thyroid nodules. We expect Mark’s considerable experience with both government and commercial payors will enhance our reimbursement efforts and improve our billings and cash collections.”

“Genomic and molecular diagnostics are making the promise of personalized medicine a reality, and I am delighted to be joining Rosetta at this exciting time in its growth. I look forward to executing a dynamic sales and marketing strategy to drive the market penetration of RosettaGX Reveal while expanding use of our entire solid tumor and urologic oncology offerings to a broader market where an increasing number of patients may truly benefit,” commented Mr. Willig.

Mr. Willig earned a B.S. in Communications from the University of Missouri.



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In






Related Categories

Corporate News, Management Changes, Management Comments

Related Entities

Definitive Agreement

Add Your Comment